COMP <GO>
NUS vs LLY // EV/EBITDA & P/E VALUATION
Nu Skin Enterprises Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: NUS 2
— LLY 9
■ METRIC PARITY
LAST: $4.69 (-1.47%) • MKT CAP: $228.3M
valuation
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.40% | 83.64% | -14.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 32.36% | -25.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 20.15% | 2.30% | +17.85 | NUS | /fcf-yield <GO> |
| Operating Margin | 4.40% | 40.21% | -35.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 31.90% | -21.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -14.30% | 45.51% | -59.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.18% | 0.49% | +4.69 | NUS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 9.29 | -5.75 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 66.6 | -23.44 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $228.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUS REV | LLY REV | NUS GROSS % | LLY GROSS % | NUS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.49B | $65.18B | 69.4% | 83.0% | $46.0M | $16.81B |
| FY 2024 | $1.73B | $45.04B | 68.2% | 81.3% | $70.2M | $8.82B |
| FY 2023 | $1.97B | $34.12B | — | 79.3% | $118.6M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUS // BETA —
LLY // BETA 0.51